Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

417

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

October 31, 2015

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

MM-398

"Arm A: MM-398 120 mg/m2 IV Q3W~Arm C: MM-398 80mg/m2 IV Q2W"

DRUG

5 Fluorouracil

"Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks"

DRUG

Leucovorin

"Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: Leucovorin 400 mg/m2 IV every 2 weeks"

Trial Locations (79)

Unknown

Gilbert

Glendale

Scottsdale

Burbank

Duarte

Fresno

LaVerne

San Luis Obispo

Boyton Beach

Atlanta

Kansas City

St Louis

Henderson

Albuquerque

Buffalo

Columbus

Norman

Greenville

Bedford

Dallas

Tyler

Fairfax

Norfolk

Buenos Aires

Rosario

Santa Fe

Westmead

Kurralta Park

Boxhill

Heidelberg

Melbourne

Nedlands

Belo Horizonte

Ijuí

Passo Fundo

Porto Alegre

São Paulo

Montreal

Hořovice

Olomouc

Prague

Příbram

Bordeaux

Lille

Marseille

Berlin

Jens

Munich

Ulm

Budapest

Pécs

Szeged

Szolnok

Szombathely

Castellana Grotte

Genova

Legnano

Naples

Roma

Port Elizabeth

Pretoria

Western Cape

Hwasun-gun

Seoul

Alicante

Barcelona

Madrid

Santander

Valencia

Chiayi City

Kaohsiung City

Taiching

Tainan City

Taipei

Taoyuan District

Liverpool

London

Manchester

Sutton

Sponsors
All Listed Sponsors
lead

Merrimack Pharmaceuticals

INDUSTRY

NCT01494506 - Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter